Analysts Are Bullish on These Healthcare Stocks: BLPH, CALA

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bellerophon (NASDAQ: BLPH) and Calithera Bio (NASDAQ: CALA) with bullish sentiments.

Bellerophon (NASDAQ: BLPH)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Bellerophon (NASDAQ: BLPH) today and set a price target of $5. The company’s shares opened today at $0.65, close to its 52-week low of $0.43.

According to TipRanks.com, Fein is a 2-star analyst with an average return of 0.3% and a 40.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Bellerophon has an analyst consensus of Strong Buy.

Calithera Bio (NASDAQ: CALA)

In a report released today, Shaunak Deepak from H.C. Wainwright reiterated a Buy rating on Calithera Bio (NASDAQ: CALA), with a price target of $10. The company’s shares opened today at $6.95, close to its 52-week high of $7.25.

According to TipRanks.com, Deepak is ranked 0 out of 5 stars with an average return of -21.2% and a 23.3% success rate. Deepak covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Karyopharm Therapeutics, and Mirna Therapeutics Inc.

Calithera Bio has an analyst consensus of Moderate Buy.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.